-
Vivus Tumbles 70% on FDA Disapproval; Piper Jaffray Urges You to Buy Arena (ARNA, VVUS)
Friday, July 16, 2010 - 10:07amThe FDA Advisory Committee voted 9 to 7 yesterday against approval of Vivus' (NASDAQ: VVUS) Qnexa, a fat-fighting pill. Vivus tumbled 60% today on the news to just over $5. Concerns arose over Qnexa's safety, especially suicide and cardiovascular risk at high doses. Piper Jaffray believes that even...
Read More >> -
Piper Jaffray Impressed By New Regeneron Drugs (REGN)
Thursday, July 1, 2010 - 9:36amPiper Jaffray analysts Chad Messer and Edward Tenthoff visited Regeneron (NADAQ:REGN) yesterday, where they were impressed by the biotech company's new product lines. Piper Jaffray said, "Regeneron fits our thesis that well financed biotech companies with innovative drug launches over the next 2...
Read More >> -
Cytori Therapeutics (NASDAQ: CYTX) Shares Fall On News Of Launch Delay
Thursday, March 18, 2010 - 8:51amAnalysts at Piper Jaffray reiterated their underweight rating for Cytori Therapeutics (NASDAQ: CYTX) on news that Cytori’s Celution system launch will be delayed. Analysts at Piper Jaffray noted that “shares of CYTX are down 36% over the last four trading sessions since Cytori reported that the FDA...
Read More >>
